Ratings Nevro Corp.

Equities

NVRO

US64157F1030

Real-time Estimate Cboe BZX Other stock markets 12:42:45 2024-04-18 pm EDT			5-day change	1st Jan Change
12.12 ^USD	-1.42%		-7.01%	-43.31%

Apr. 15	RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	MT
Apr. 11	Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	MT

Strengths

The company is in a robust financial situation considering its net cash and margin position.
With regards to fundamentals, the enterprise value to sales ratio is at 0.77 for the current period. Therefore, the company is undervalued.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NEVRO CORP.	-43.31%	451M	C+
ABBOTT LABORATORIES	-4.49%	184B	C+
MEDTRONIC PLC	-4.17%	105B	C
BECTON, DICKINSON AND COMPANY	-5.23%	67.09B	A
DEXCOM, INC.	+8.86%	51.61B	B-
CENCORA, INC.	+15.42%	47.55B	B-
HOYA CORPORATION	+0.60%	39.95B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+7.95%	27.62B	A-
SARTORIUS STEDIM BIOTECH	-12.48%	25.74B	B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.07%	25.62B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes